CN114146122A - Traditional Chinese medicine composition for treating anorexia - Google Patents

Traditional Chinese medicine composition for treating anorexia Download PDF

Info

Publication number
CN114146122A
CN114146122A CN202010935222.8A CN202010935222A CN114146122A CN 114146122 A CN114146122 A CN 114146122A CN 202010935222 A CN202010935222 A CN 202010935222A CN 114146122 A CN114146122 A CN 114146122A
Authority
CN
China
Prior art keywords
traditional chinese
radix
chinese medicine
fructus aurantii
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010935222.8A
Other languages
Chinese (zh)
Inventor
程国良
关永霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunan Pharmaceutical Group Corp
Original Assignee
Lunan Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunan Pharmaceutical Group Corp filed Critical Lunan Pharmaceutical Group Corp
Priority to CN202010935222.8A priority Critical patent/CN114146122A/en
Publication of CN114146122A publication Critical patent/CN114146122A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/237—Notopterygium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating anorexia. The traditional Chinese medicine composition is mainly prepared from notopterygium root, radix angelicae pubescentis, poria cocos, divaricate saposhnikovia root, schizonepeta, ligusticum wallichii, platycodon grandiflorum, radix bupleuri, radix peucedani, fructus aurantii and liquorice. Pharmacological experiments show that the traditional Chinese medicine composition can obviously increase the content of peripheral blood and central neuropeptide of rats, thereby effectively improving appetite and increasing food intake and weight; the appetite of the rat can be improved by promoting the content of the beta-endorphin of the rat to be increased; and the gastrointestinal peristalsis of the rat is promoted by improving the content of motilin and gastrin of the rat, the gastrointestinal motility of the rat is enhanced, the gastric emptying of the rat is promoted, and the anorexia is improved and promoted well.

Description

Traditional Chinese medicine composition for treating anorexia
Technical Field
The invention relates to a composition, in particular to a traditional Chinese medicine composition for treating anorexia, and belongs to the technical field of traditional Chinese medicines.
Background
Anorexia (anorexia), also known as anorexia, is one of the most common clinical symptoms, mainly manifested by decreased appetite of patients, resulting in decreased appetite to different degrees, and even anorexia in severe cases. Can be caused by various reasons, such as organic lesions of the digestive system, systemic diseases, mental factors, side effects of drugs, and the like.
Loss of appetite can cause wasting, weight loss, malnutrition for a long period of time. The deficiency of three substances, namely protein, fat and carbohydrate, the deficiency of various vitamins and trace elements, the blood pressure reduction, bradycardia, hypothermia and the like can occur in severe cases, and the immunity of the organism can also be reduced. Some patients may have mental symptoms such as anxiety and listlessness due to long-term anorexia.
Anorexia is mainly caused by diseases of digestive tract, such as gastritis, hepatitis, cholecystitis, etc., and also can be seen in other systemic diseases such as hypothyroidism, severe anemia, etc., and is influenced by some medicines or mental factors.
Anorexia is a long-term symptom of loss or disappearance of appetite. There are two major pathophysiological factors: a method for treating gastrointestinal diseases comprises affecting digestive function due to local or systemic diseases, and reducing gastrointestinal smooth muscle tension, digestive juice secretion, and enzyme activity; the other is that the central nervous system is affected by the stimulation of the internal and external environment of the human body, so that the regulation of the digestion function is out of balance.
Anorexia is common in children of 1-6 years old, is a common eating behavior problem in children health care outpatient service, and is also a main reason for difficulty in feeding infants and nutrient deficiency. Generally expressed as refusing to eat certain food, choosing favorite meal, unwilling to try new food, lacking interest in food, etc.
Common causes include poor eating habits, infections, gastrointestinal disorders, metabolic and endocrine disorders, and nutritional disorders including increased vitamin A, D poisoning in recent years. Long-term anorexia can lead to malnutrition, growth and development disorders and psychobehavioral abnormalities.
Disclosure of Invention
The inventor explains that the invention is further developed on the basis of the existing product 'Jingfang granules', and the new application of the Jingfang granules comes from clinical use feedback.
One of the purposes of the invention is to provide a traditional Chinese medicine composition for treating anorexia, which is mainly prepared from notopterygium root, radix angelicae pubescentis, poria cocos, radix sileris, schizonepeta, ligusticum wallichii, platycodon grandiflorum, radix bupleuri, radix peucedani, fructus aurantii and liquorice;
the Chinese medicinal composition comprises the following medicinal materials in part by weight:
5-20 parts of schizonepeta, 5-20 parts of divaricate saposhnikovia root and 10-20 parts of notopterygium root
10-20 parts of pubescent angelica root, 5-20 parts of bupleurum root, 5-20 parts of peucedanum root
10-20 parts of ligusticum wallichii, 5-30 parts of fructus aurantii, 10-30 parts of poria cocos
10-20 parts of platycodon grandiflorum and 5-10 parts of liquorice.
Preferably, the Chinese medicinal composition comprises the following medicinal materials in parts by weight:
10-20 parts of schizonepeta, 10-20 parts of divaricate saposhnikovia root and 10-20 parts of notopterygium root
10-20 parts of radix angelicae pubescentis, 10-20 parts of radix bupleuri, 10-20 parts of radix peucedani
10-20 parts of ligusticum wallichii, 10-25 parts of fructus aurantii, 10-25 parts of poria cocos, and the like
10-20 parts of platycodon grandiflorum and 5-10 parts of liquorice.
Further preferably, the Chinese medicinal composition comprises the following medicinal materials in parts by weight:
15 parts of schizonepeta, 15 parts of divaricate saposhnikovia root and 15 parts of notopterygium root
Radix angelicae pubescentis 15 parts by weight of radix bupleuri 15 parts by weight of radix peucedani 15 parts by weight
15 parts of ligusticum wallichii, 15 parts of fructus aurantii and 15 parts of poria cocos
15 parts of platycodon grandiflorum and 5 parts of liquorice.
The anorexia of the present invention can be caused by various reasons, such as digestive tract diseases, systemic diseases, mental factors, drug action, etc.
The digestive tract diseases can be stomach diseases (such as gastric cancer, acute gastritis, chronic gastritis, duodenal ulcer with pyloric obstruction), intestinal tract diseases (such as intestinal obstruction, tuberculosis, etc.), liver diseases (such as chronic hepatitis, liver cirrhosis, liver cancer, etc.), biliary tract diseases (such as acute and chronic cholecystitis, bile duct cancer, etc.), and pancreatic diseases (such as acute and chronic pancreatitis, pancreatic cancer, etc.).
The systemic diseases can be hyperpyrexia, electrolyte and acid-base imbalance caused by various reasons (such as hyponatremia, hypochloromemia, hypokalemia, hyperkalemia, respiratory acid and alkalosis caused by various reasons, metabolic acid and alkalosis caused by various reasons), endocrine diseases (such as hypothyroidism, adrenocortical hypofunction, hypophysis and the like) and other diseases (such as severe anemia, uremia and vitamin deficiency).
The medicine with the above side effects can be aminophylline, ammonium chloride, digitalis, chlorotoxin, aspirin, erythromycin, etc.
Specifically, common diseases causing anorexia include neurosis, depression, emotional anorexia, dyspepsia syndrome, irritable bowel syndrome, acute and chronic gastritis, enteritis, peptic ulcer, pyloric obstruction, gastric cancer, intestinal cancer, appendicitis, inflammatory bowel disease, acute and chronic hepatitis, posthepatitic syndrome, liver cirrhosis, liver cancer, cholecystitis, cholelithiasis, postcholecystectomy syndrome, acute and chronic pancreatitis, pancreatic cancer, chronic nephritis, pyelonephritis, urinary system infection, renal insufficiency, arrhythmia, hypothyroidism, adrenocortical insufficiency, medullary thyroid cancer, electrolyte metabolism disorder, hyperparathyroidism, intestinal parasites, etc.
The second purpose of the invention is to provide the application of the traditional Chinese medicine composition in preparing the medicine for treating anorexia.
The invention also aims to provide a preparation method of the traditional Chinese medicine composition, which mainly comprises the following steps:
step A: distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and collecting the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 10-40% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs in water, and concentrating the decoction for later use;
step E: and D, mixing the percolate obtained in the step C and the decoction obtained in the step D, concentrating, and adding the volatile oil obtained in the step A to obtain the composition.
Preferably, the preparation method mainly comprises the following steps:
step A: distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and collecting the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into 15-30% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs in water, and concentrating the decoction into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, concentrating the mixture into clear paste, and adding the volatile oil obtained in the step A to obtain the ointment.
Further preferably, the preparation method mainly comprises the following steps:
step A: distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and collecting the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 25% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs in water, and concentrating the decoction into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, concentrating the mixture into clear paste, and adding the volatile oil obtained in the step A to obtain the ointment.
The invention also aims to provide a traditional Chinese medicine preparation containing the traditional Chinese medicine composition, wherein the traditional Chinese medicine preparation is prepared from the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials;
preferably, the Chinese medicinal preparation is a clinically acceptable oral preparation;
further preferably, the clinically acceptable oral preparation is one or more of pills, capsules, tablets, granules or liquid oral preparations;
even more preferably, the granules are warrior granules.
Compared with the prior art, the invention has the following remarkable technical effects:
1. the traditional Chinese medicine composition can obviously increase the content of peripheral blood and central neuropeptide of rats, thereby effectively improving appetite and increasing food intake and weight.
2. The traditional Chinese medicine composition can promote the appetite of rats by promoting the content of the beta-endorphin of the rats to increase; the gastrointestinal peristalsis of the rat is promoted by improving the content of motilin and gastrin of the rat, the gastrointestinal motility of the rat is enhanced, the gastric emptying of the rat is promoted, and the anorexia is improved and promoted well.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The present invention is further illustrated by the following examples, which are intended to be purely exemplary and are not intended to limit the scope of the invention, as various equivalent modifications of the invention will occur to those skilled in the art upon reading the present disclosure and fall within the scope of the appended claims.
EXAMPLE 1 preparation of granules
Prescription:
75g of schizonepeta, 75g of divaricate saposhnikovia root, 75g of incised notopterygium rhizome, 75g of pubescent angelica root, 75g of Chinese thorowax root, 75g of whiteflower hogfennel root and 75g of common hogfennel root
75g of ligusticum wallichii, 75g of fructus aurantii, 75g of poria cocos, 75g of platycodon grandiflorum and 25g of liquorice;
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 25% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, preparing into granules, drying, adding the volatile oil obtained in the step A, and uniformly mixing to obtain the traditional Chinese medicine.
Example 2 preparation of granules
Prescription:
herba Schizonepetae 20g, radix Saposhnikoviae 10g, Notopterygii rhizoma 20g, radix Angelicae Pubescentis 10g, bupleuri radix 20g, radix Peucedani 10g
20g of ligusticum wallichii, 10g of fructus aurantii, 25g of poria cocos, 10g of platycodon grandiflorum and 10g of liquorice;
the preparation method is the same as example 1.
EXAMPLE 3 tablet preparation
Prescription:
herba schizonepetae 10g, ledebouriella root 20g, notopterygium root 10g, pubescent angelica root 20g, bupleurum root 10g, peucedanum root 20g
10g of ligusticum wallichii, 25g of fructus aurantii, 10g of poria cocos, 10g of platycodon grandiflorum, 20g of liquorice and 5g of liquorice;
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 15% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, granulating, drying, adding the volatile oil obtained in the step A, uniformly mixing, granulating, adding a proper amount of auxiliary materials, uniformly mixing, and tabletting to obtain the traditional Chinese medicine.
Example 4 oral liquid preparation
Prescription:
herba schizonepetae 5g, divaricate saposhnikovia root 20g, notopterygium root 10g, pubescent angelica root 20g, bupleurum root 5g, peucedanum root 20g
10g of ligusticum wallichii, 5g of fructus aurantii, 30g of poria cocos, 10g of platycodon grandiflorum and 10g of liquorice;
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 10% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of sucrose, mixing uniformly, adding the volatile oil obtained in the step A, mixing uniformly, and adding water to 1000ml to obtain the traditional Chinese medicine composition.
EXAMPLE 5 syrup preparation
Prescription:
herba Schizonepetae 20g, radix Saposhnikoviae 5g, Notopterygii rhizoma 20g, radix Angelicae Pubescentis 10g, bupleuri radix 20g, radix Peucedani 5g
20g of ligusticum wallichii, 30g of fructus aurantii, 10g of poria cocos, 20g of platycodon grandiflorum and 5g of liquorice;
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 40% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, mixing uniformly, adding 500ml of the volatile oil and the simple syrup obtained in the step A, mixing uniformly, standing, filtering, and adding water to 1000ml to obtain the traditional Chinese medicine.
EXAMPLE 6 Capsule preparation
Prescription:
75g of schizonepeta, 75g of divaricate saposhnikovia root, 75g of incised notopterygium rhizome, 75g of pubescent angelica root, 75g of Chinese thorowax root, 75g of whiteflower hogfennel root and 75g of common hogfennel root
75g of ligusticum wallichii, 75g of fructus aurantii, 75g of poria cocos, 75g of platycodon grandiflorum and 25g of liquorice;
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 30% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, granulating, drying, adding the volatile oil obtained in the step A, uniformly mixing, granulating, drying, crushing and encapsulating to obtain the capsule.
EXAMPLE 7 pellet preparation
Prescription:
75g of schizonepeta, 75g of divaricate saposhnikovia root, 75g of incised notopterygium rhizome, 75g of pubescent angelica root, 75g of Chinese thorowax root, 75g of whiteflower hogfennel root and 75g of common hogfennel root
75g of ligusticum wallichii, 75g of fructus aurantii, 75g of poria cocos, 75g of platycodon grandiflorum and 25g of liquorice;
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 25% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, preparing into granules, drying, adding the volatile oil obtained in the step A, uniformly mixing, drying, crushing, sieving, adding 40-60 g of refined honey and a proper amount of water, pelleting, and drying to obtain the traditional Chinese medicine.
Second, pharmacological experiment
In order to verify the efficacy of the traditional Chinese medicine composition for treating anorexia and anorexia, the inventor carries out related pharmacodynamic test research. It should be noted that the medicines selected in the pharmacodynamic tests below are the medicines obtained by the representative formula and the preparation method thereof; the inventor also conducts pharmacodynamic experiments on the medicines obtained by the other formulas and the preparation methods, and the experimental results show that the medicines obtained by the other formulas and the preparation methods have the same or similar effects, but the medicines are not exhaustive due to space limitations.
In addition, the pharmacodynamic experiments described below only take part of animal models as examples to verify the efficacy of the present invention, and related pharmacodynamic experiments are also performed by the inventor to show that the animal models have the same or similar effects, and the results are not exhaustive.
The inventor explains that the following experimental studies are carried out on the basis of the safety of the drug proved by acute toxicity tests and long-term toxicity tests, and the administration dose in the experimental studies is within a safe dose range.
First, the influence of the traditional Chinese medicine composition on appetite and NPY expression of rats in a post-chemotherapy anorexia model
1 Material
1.1 animals:
wistar rat, SPF grade, 180-220 g, laboratory animal license number: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Granules obtained in examples 1 and 2 of the present invention
Cisplatin injection (Chinese medicine standard character H20043888)
1.2.3 dosage
Example 1 granules: 2.925g/kg (high dose), 5.85g/kg (medium dose), 11.7g/kg (low dose)
Example 2 granules: 5.85g/kg
2. Modeling, grouping and administering drugs
2.1 Molding
The cisplatin injection is injected into abdominal cavity of rat at 5mg/kg, and 5 days later, the cisplatin injection is injected again at 5mg/kg, 2 times.
2.2 grouping and administration
Taking 50 successfully molded rats, and randomly dividing the rats into a model group, three dose groups (high, medium and low) in example 1 and 10 dose groups in example 2; another 10 normal rats were selected as a blank group.
Example 1 three dose groups and example 2 groups are respectively administered with corresponding drugs by intragastric administration, and a model group and a blank group are respectively administered with physiological saline with the same amount by intragastric administration; once daily for 14 consecutive days.
3 observation index
3.1 rat food intake and weight changes before and after the experiment
On the 0 th day of the experiment, the 7 th day and the 14 th day of the administration, the change of the food intake and the body weight of the rat was observed.
3.2 Change in the amount of rat hypothalamic and plasma neuropeptide Y (NPY) before and after the experiment
After the last administration, fasting overnight, killing the next day, collecting whole blood, centrifuging, and collecting plasma; separating whole brain, storing in liquid nitrogen, taking out whole brain the next day, separating hypothalamus, weighing, and making hypothalamus tissue homogenate; radioimmunoassay measures the amount of NPY in the hypothalamus and plasma.
3.3 statistical treatment
Statistical analysis is carried out on the obtained data by adopting SPSS22.0 software, and the data is measured
Figure BDA0002671686710000091
The results are shown in the following table, wherein the comparison among the groups is carried out by adopting one-factor analysis of variance, and the analysis between the two groups is carried out by adopting an independent sample T test mode. With P<A difference of 0.05 is statistically significant.
4. Results and conclusions
4.1 rat food intake and weight changes before and after the experiment
Compared with the model group, the weight and the food intake of the rats in each administration group are obviously increased, and the difference has statistical significance (P is less than 0.01).
TABLE 1 comparison of body weight changes in rats of various groups
Figure BDA0002671686710000092
Figure BDA0002671686710000093
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01。
TABLE 2 comparison of the change in food intake of rats in each group
Figure BDA0002671686710000094
Figure BDA0002671686710000095
Figure BDA0002671686710000101
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01。
4.2 Change in the content of rat hypothalamic and plasma neuropeptide Y (NPY) before and after the experiment
Compared with the blank group, the NPY content in the hypothalamus and the blood plasma of the rat in the model group is obviously reduced, and the difference has statistical significance (P is less than 0.01); suggesting that the appetite decrease is related to the decrease of NPY content in hypothalamus and blood plasma.
Compared with the model group, the NPY content in the hypothalamus and the blood plasma of the rat of each administration group is obviously reduced, and the difference has statistical significance (P is less than 0.01); the Chinese medicinal composition can improve appetite and increase food intake and body weight by increasing the content of peripheral blood and central nerve skin of rats.
TABLE 3 comparison of changes in NPY in hypothalamus and plasma in rats in each group
Figure BDA0002671686710000102
Figure BDA0002671686710000103
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01。
secondly, the traditional Chinese medicine composition of the invention has the function of improving rats with anorexia
1 Material
1.1 animals:
SD rat, SPF grade, 140-160 g, the license number of experimental animal: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Granules obtained in examples 1 and 2 of the present invention
Xiangsha stomach harmonizing pill (Chinese medicine standard Z11020928)
1.2.2 dosage
Example 1 granules: 2.925g/kg (high dose), 5.85g/kg (medium dose), 11.7g/kg (low dose)
Example 2 granules: 5.85g/kg
Xiangsha stomach harmonizing pill: 1.62g/kg
2. Modeling, grouping and administering drugs
2.1 Molding
The rats are fed with special feed (fish floss, milk powder, corn flour, soybean flour, white sugar, fresh eggs and fresh fat meat are mixed according to the proportion of 1:1:1:2:1:1.8: 2). The change of food intake and physical quality is recorded every day, the average decrease of the food intake of rats is 20-30%, or the physical quality is 10-15% lower than that of the rats fed normally, and the occurrence of significant symptoms such as squinting, somnolence, coarse hair, no diarrhea and the like is taken as the success of modeling.
2.2 grouping and administration
Taking 50 successfully molded rats, and randomly dividing the rats into a model group, three dose groups (high, medium and low) in example 1 and 10 dose groups in example 2; another 10 rats were fed normally and were blank groups.
Example 1 three dose groups and example 2 groups are respectively administered with corresponding drugs by intragastric administration, and a model group and a blank group are respectively administered with physiological saline with the same amount by intragastric administration; for 14 consecutive days.
Except the blank group, the rest groups are continuously fed by special feed.
3 observation index
3.1 rat food intake and weight changes
During dosing, each group of rats was weighed for body mass and food intake.
3.2 gastric emptying
After fasting for 36h after the last administration, each group was gavaged with 2.0 mL/dose of nutritional semisolid paste (containing 10g of sodium carboxymethylcellulose, 16g of milk powder, 8g of white granulated sugar, 8g of starch and 2g of activated carbon powder). 20min later, anaesthetizing, dissecting the abdominal cavity, ligating the cardia and pylorus, taking the stomach, wiping with filter paper, weighing the whole weight, cutting the body of the stomach along the greater curvature of the stomach, washing off the content in the stomach, wiping, weighing the net weight, and taking the difference of the total weight and the net weight of the stomach as the weight of the residue in the stomach.
3.3 plasma beta-endorphin, motilin and gastrin assays
The abdominal aorta of the rat is bled and placed in a blood collection tube, centrifuged, the supernatant is taken, the average optical density value (D value) of the supernatant is measured according to the method of the specification of a beta-endorphin, motilin and gastrin kit, and the content is calculated.
3.4 statistical treatment
Statistical analysis is carried out on the obtained data by adopting SPSS22.0 software, and the data is measured
Figure BDA0002671686710000111
The results of the two groups are analyzed by independent sample T test mode. With P<A difference of 0.05 is statistically significant.
4. Results and conclusions
4.1 general case
In the experimental process, the phenomena of poor appetite, emaciation, weight reduction, listlessness, squinting, lacklustered hair color, crouched and gathered pile, cold feeling, easy fatigue and the like appear in rats compared with blanks in the modeling process. The mental state of the rats treated by the drug administration is obviously improved, and the phenomena of squinting, coarse hair, dorsum arcae and the like are improved, and the rat mental state is not different from that of the rats in the blank group.
4.2 Change before and after animal body Mass modeling and food intake Change in each group
4.2.1 body Mass comparison of the body masses of the various groups of experimental animals is shown in Table 1.
The difference between the body mass of each group on the 14 th day of molding and that of the blank group is obvious until the body mass difference on the 28 th day of molding is obvious (P is less than 0.01), and the average body mass of the molded rat is about 10 percent lower than that of the blank control group;
after 2 weeks of continuous gavage, the body mass of rats in each administration group is obviously increased compared with that in the model group, and the difference has statistical significance (P is less than 0.01). The traditional Chinese medicine composition has obvious increasing effect on the physique quantity of rats with model anorexia.
TABLE 4 comparison of body weights of rats in different periods of time
Figure BDA0002671686710000121
Figure BDA0002671686710000122
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01；
compared with the group of the xiangsha stomach-harmonizing pills,&P＜0.05，￥P＜0.01。
4.2.2 food intake
And (3) weighing the feed addition amount and the residual amount at regular time every day, and calculating the average food intake of each group of rats and the average food intake change condition of each group of experimental animals. By the 28 th day, the food intake of rats of each model is reduced and is about 30 percent lower than that of the blank group, which indicates that the model is successfully made;
after 2 weeks of continuous administration, the food intake of each administration group is increased, which shows that the traditional Chinese medicine composition has certain improvement effect on the food intake of rats with model anorexia.
TABLE 5 comparison of food intake at different periods in rats in each group
Figure BDA0002671686710000131
Figure BDA0002671686710000132
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01；
compared with the group of the xiangsha stomach-harmonizing pills,&P＜0.05，￥P＜0.01。
4.3 Biochemical index
Effect on beta-endorphins: comparing the model group with the blank group, wherein the measured value is lower than that of the blank group, and the difference is statistically different (P is less than 0.01), which indicates that the molding is successful;
compared with the model group, the rats of each administration group have obviously increased content of beta-endorphin, and the difference has statistical difference (P is less than 0.01), which shows that the traditional Chinese medicine composition can increase the content of the beta-endorphin in the plasma of the rats, thereby promoting appetite and improving anorexia.
Effects on the changes in motilin content: comparing the model group with the blank group, wherein the measured value is lower than that of the blank group, and the difference is statistically different (P is less than 0.01), which indicates that the molding is successful;
compared with the model group, the rats in each administration group have obviously increased motilin content, and the difference has statistical difference (P is less than 0.01), which shows that the traditional Chinese medicine composition can improve the gastrointestinal function, promote gastric emptying and improve anorexia by adjusting the content of the motilin.
Effect on gastrin content change: comparing the model group with the blank group, wherein the measured value is lower than that of the blank group, and the difference is statistically different (P is less than 0.01), which indicates that the molding is successful;
compared with the model group, the rats in each administration group have obviously increased gastrin content, and the difference has statistical difference (P is less than 0.01), which shows that the traditional Chinese medicine composition can promote the secretion function of the gastrointestinal tract of animals, contract the stomach body, increase the movement of the gastrointestinal tract, promote the relaxation of pyloric sphincter and has good effect of promoting gastric emptying.
TABLE 6 Biochemical index comparison of rats in each group
Figure BDA0002671686710000133
Figure BDA0002671686710000134
Figure BDA0002671686710000141
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01；
compared with the group of the xiangsha stomach-harmonizing pills,&P＜0.05，￥P＜0.01。
4.4 gastric emptying
Compared with the model group, the rats in each administration group have statistical difference (P is less than 0.01), the residue rate is obviously lower than that in the model group, and the spleen-invigorating granules can obviously promote gastric emptying, enhance gastric peristalsis and improve anorexia.
TABLE 7 comparison of gastric emptying in groups of rats
Figure BDA0002671686710000142
Figure BDA0002671686710000143
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01；
compared with the group of the xiangsha stomach-harmonizing pills,&P＜0.05，￥P＜0.01。
the traditional Chinese medicine composition can promote the appetite of rats by promoting the content of the beta-endorphin of the rats to increase; the gastrointestinal peristalsis of the rat is promoted by improving the content of motilin and gastrin of the rat, the gastrointestinal motility of the rat is enhanced, the gastric emptying of the rat is promoted, and the anorexia is improved and promoted well.

Claims (10)

1. The application of a traditional Chinese medicine composition in preparing a medicine for treating anorexia is characterized in that the traditional Chinese medicine composition is mainly prepared from notopterygium root, radix angelicae pubescentis, poria cocos, radix sileris, schizonepeta, ligusticum wallichii, platycodon grandiflorum, radix bupleuri, radix peucedani, fructus aurantii and liquorice.
2. The use as claimed in claim 1 wherein the anorexia is caused by one or more of digestive disorders, systemic disorders, psychogenic factors, and pharmacological effects.
3. The use of claim 2, wherein the digestive tract disease is one or more of a gastric disease, an intestinal disease, a liver disease, a biliary tract disease, and a pancreatic disease.
4. The use according to claim 1, wherein the systemic disease is one or more of hypothyroidism, hypoadrenocortical function, hypopituitarism.
5. Use of the Chinese medicinal composition of claim 1 in the preparation of a medicament for the treatment of anorexia.
6. The use of claims 1-5, wherein the Chinese medicinal composition is prepared from the following raw materials:
Figure FDA0002671686700000011
7. the use of claim 6, wherein the Chinese medicinal composition is prepared from the following raw materials:
Figure FDA0002671686700000012
8. the use of claim 7, wherein the Chinese medicinal composition is prepared from the following raw materials:
Figure FDA0002671686700000013
9. a traditional Chinese medicine preparation, which is characterized in that the traditional Chinese medicine preparation is prepared from the traditional Chinese medicine composition of any one of claims 1 to 8 and pharmaceutically acceptable auxiliary materials; preferably, the Chinese medicinal preparation is a clinically acceptable oral preparation; further preferably, the clinically acceptable oral preparation is one or more of pills, capsules, tablets, granules or liquid oral preparations; more preferably, the granules are warrior granules.
10. A method for preparing the traditional Chinese medicine composition of any one of claims 1 to 8, wherein the method for preparing comprises the following steps:
step A: distilling herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and collecting the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 10-40% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs in water, and concentrating the decoction for later use;
step E: and D, mixing the percolate obtained in the step C and the decoction obtained in the step D, concentrating, and adding the volatile oil obtained in the step A to obtain the composition.
CN202010935222.8A 2020-09-08 2020-09-08 Traditional Chinese medicine composition for treating anorexia Pending CN114146122A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010935222.8A CN114146122A (en) 2020-09-08 2020-09-08 Traditional Chinese medicine composition for treating anorexia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010935222.8A CN114146122A (en) 2020-09-08 2020-09-08 Traditional Chinese medicine composition for treating anorexia

Publications (1)

Publication Number Publication Date
CN114146122A true CN114146122A (en) 2022-03-08

Family

ID=80460770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010935222.8A Pending CN114146122A (en) 2020-09-08 2020-09-08 Traditional Chinese medicine composition for treating anorexia

Country Status (1)

Country Link
CN (1) CN114146122A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361952A (en) * 2008-09-19 2009-02-11 何茁 Traditional Chinese medicine preparation for treating cold
CN101584745A (en) * 2009-06-29 2009-11-25 北京大北农科技集团股份有限公司 Preparation for new antivirus Chinese medicine formulation for animal
CN101664467A (en) * 2008-09-03 2010-03-10 天津生机集团股份有限公司 Microbial fermentation preparation of Jingfang toxicity-removing composition
CN102362909A (en) * 2011-06-29 2012-02-29 纽素乐必佳（天津）药业集团有限公司 Method for preparing schizonepeta and divaricate saposhnikovia root oral liquid for removing toxin
CN114073731A (en) * 2020-08-14 2022-02-22 鲁南制药集团股份有限公司 A Chinese medicinal composition for treating abdominal pain and diarrhea

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101664467A (en) * 2008-09-03 2010-03-10 天津生机集团股份有限公司 Microbial fermentation preparation of Jingfang toxicity-removing composition
CN101361952A (en) * 2008-09-19 2009-02-11 何茁 Traditional Chinese medicine preparation for treating cold
CN101584745A (en) * 2009-06-29 2009-11-25 北京大北农科技集团股份有限公司 Preparation for new antivirus Chinese medicine formulation for animal
CN102362909A (en) * 2011-06-29 2012-02-29 纽素乐必佳（天津）药业集团有限公司 Method for preparing schizonepeta and divaricate saposhnikovia root oral liquid for removing toxin
CN114073731A (en) * 2020-08-14 2022-02-22 鲁南制药集团股份有限公司 A Chinese medicinal composition for treating abdominal pain and diarrhea

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
彭成 等: "《中国临床药物大辞典 中药成方制剂卷 上》", 31 August 2018, 中国医药科技出版社 *
杨明武 等: "母猪产后不食的综合防治措施", 《畜牧兽医科技信息》 *

Similar Documents

Publication Publication Date Title
CN109674958B (en) Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof
CN102526478B (en) Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar
CN106074971A (en) A kind of hypoglycemic traditional Chinese medicine composition and preparation method and application
CN114246918A (en) Traditional Chinese medicine composition for treating hashimoto thyroiditis and preparation method thereof
CN101461932B (en) Medicament composition for treating children&#39;s damp-heat diarrhea induced by spleen insufficiency and preparation method thereof
CN101259191B (en) Fat-reducing health products and producing method thereof
US20220047658A1 (en) Tcm addition and subtraction prescription used prevention/treatment of metabolic syndrome and complications
CN115607638A (en) Traditional Chinese medicine composition for infantile indigestion with food retention and preparation method thereof
CN114146122A (en) Traditional Chinese medicine composition for treating anorexia
CN101491605A (en) Combination with blood sugar reducing function and preparation method thereof
CN100579564C (en) Medicine for curing gout and its preparing method
CN107693555A (en) A kind of medicine and purposes for treating diabetes
CN101229329A (en) Indigestion tablet and preparing process thereof
CN104983759A (en) Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof
CN102335362B (en) Traditional Chinese medicine for treating insulin resistance of type 2 diabetes
CN106722918A (en) A kind of hypoglycemia healthcare food and preparation method thereof
CN114272295A (en) Traditional Chinese medicine composition for treating diabetic acromelic gangrene
CN108143875B (en) Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof
CN108704036A (en) A kind of Chinese traditional compound medicine and preparation method thereof for treating gout
CN103893512B (en) A kind of Chinese medicine composition for treating urarthritis
CN113694105B (en) Composition with blood fat reducing function and application thereof
JPH0798753B2 (en) Composition for lowering blood glucose level
CN107669860A (en) A kind of Chinese medicine composition and its application with blood sugar reducing function
CN1284592C (en) Chinese materia medica preparation for nourishing face and preparation method
CN108261511A (en) A kind of composition with antiobesity action and preparation method thereof and purposes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination